Skip to main content
Sun Pharmaceutical Industries Ltd. logo

Sun Pharmaceutical Industries Ltd. — Investor Relations & Filings

Ticker · SUNPHARMA ISIN · INE044A01036 LEI · 335800KJ7GE29LB4SS73 BSE.NS Manufacturing
Open in API
Filings indexed 1,407 across all filing types
Latest filing 2026-03-16 Regulatory Filings
Country IN India
Listing BSE.NS SUNPHARMA

About Sun Pharmaceutical Industries Ltd.

https://sunpharma.com/

Sun Pharmaceutical Industries Ltd. is a global leader in specialty generic pharmaceuticals, focused on developing, manufacturing, and marketing a comprehensive range of pharmaceutical formulations and active pharmaceutical ingredients (APIs). The company’s extensive portfolio covers diverse therapeutic segments, including cardiology, psychiatry, neurology, gastroenterology, ophthalmology, dermatology, and orthopedics. It provides high-quality, affordable medicines across more than 100 markets worldwide, serving both chronic and acute care needs. A significant emphasis is placed on research and development to produce complex generics and innovative specialty products. The organization maintains a robust global manufacturing footprint, operating facilities that comply with stringent international regulatory standards. Its offerings encompass generics, branded generics, specialty medications, and over-the-counter products, aimed at improving patient outcomes globally.

Recent filings

Filing Released Lang Actions
Press Release
Regulatory Filings Classification · 95% confidence The document is a press release from Sun Pharmaceutical Industries Limited announcing the US FDA acceptance of a Supplemental Biologics License Application (sBLA) for ILUMYA for the treatment of adults with active psoriatic arthritis. It includes details about the drug, clinical studies, safety information, and company background. There are no financial statements, regulatory certifications, or detailed financial data. The document is an official announcement of a regulatory event (FDA acceptance of sBLA) and not a financial report or management discussion. It is not a report publication announcement since it is a substantive press release. The document fits best under the category of Regulatory Filings (RNS) as it is a general regulatory announcement related to the company's product and FDA regulatory process.
2026-03-16 English
Investor Presentation
Investor Presentation Classification · 100% confidence The document is titled 'Investor Presentation' and is explicitly described as such in the subject line and body text. It includes detailed financial highlights, business operations, growth strategies, ESG performance, and market positioning. The document is lengthy (15,000 characters) and contains comprehensive presentation content rather than a brief announcement or a certification. There is no indication that this is an annual report, earnings release, or regulatory filing. The presence of slides and structured presentation format confirms it is an investor presentation. Therefore, the correct classification is Investor Presentation (IP).
2026-02-24 English
Copy of Newspaper Publication
Regulatory Filings Classification · 95% confidence The document is an intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, regarding the opening of a special window for transfer of physical shares. It includes details about the regulatory circular, the period of the special window, instructions for investors, and mentions newspaper advertisements published by the company. The document is a formal announcement to stock exchanges and investors about this regulatory event and related advertisements. It does not contain financial statements, management discussion, or detailed financial data. It is not a report itself but an announcement of a regulatory event and related advertisements. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2026-02-06 English
Analysts/Institutional Investor Meet/Con. Call Updates
Call Transcript Classification · 100% confidence The document is titled 'Q3 FY26 Earnings Call Transcript' and includes detailed discussion of quarterly financial results, business updates, product launches, and a Q&A session. It references the third quarter of fiscal year 2026, includes consolidated financial figures such as sales, EBITDA, net profit, EPS, and segment performance. The document is a full transcript of the earnings conference call, including management commentary and participant questions. This matches the definition of a Call Transcript (CT), which is a full text transcript of company conference calls like earnings calls with Q&A. The document is not a brief announcement or a report publication notice, but a detailed transcript. Therefore, the correct classification is CT with high confidence.
2026-02-04 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is a short notice dated 03 February 2026 from Sun Pharmaceutical Industries Limited addressed to stock exchanges. It announces the schedule of upcoming analyst and institutional investor meetings, specifying dates, venues, and types of meetings. It explicitly states that no unpublished price sensitive information will be disclosed. The document is an intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which relates to disclosure obligations for listed companies. The document does not contain any financial data, detailed report, or results, nor does it attach or announce the publication of a report. It is essentially a regulatory announcement about investor meetings. Given the short length (2032 characters) and the nature of the content, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2026-02-03 English
Updates
Environmental & Social Information Classification · 95% confidence The document is titled 'Sustainability Report for the financial year 2024-25' and contains detailed information on the company's environmental, social, and governance (ESG) performance, including sections on ESG performance highlights, governance, risk management, stakeholder engagement, environmental stewardship, workforce resilience, and community impact. It references frameworks such as GRI Standards, UN Global Compact, TCFD, and includes external assurance. The content is comprehensive and focused on sustainability and corporate social responsibility rather than financial results or regulatory filings. This matches the definition of an Environmental & Social Information report (SR). The document length is substantial (15,000 characters), indicating it is the report itself, not just an announcement or summary. Therefore, the correct classification is SR with high confidence.
2026-02-02 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.